Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia

20253 citationsJournal Article

Authors

Hanny Al‐Samkari · Massachusetts General Hospital

Josefien Hessels · St. Antonius Ziekenhuis

Antoni Riera‐Mestre · Bellvitge University Hospital

Sophie Dupuis‐Girod · Inserm

Thibaut Van Zele · Ghent University Hospital

Vicente Gómez del Olmo · Instituto Ramón y Cajal de Investigación Sanitaria

Pamela G Hodges

Abstract

The safety profile of engasertib was similar to that of placebo except for mild-to-moderate rash, which resolved in most patients who continued to receive the drug. Engasertib treatment was associated with decreases in epistaxis frequency and duration. (Funded by Vaderis Therapeutics; ClinicalTrials.gov number, NCT05406362.).

Topics & Keywords

Vascular Anomalies and Treatments Otitis Media and Relapsing Polychondritis Gastrointestinal Bleeding Diagnosis and Treatment

Publication Details

Published in: New England Journal of Medicine

Volume 393, Issue 21, pp. 2131-2141

DOI: 10.1056/nejmoa2504411

Field-Weighted Citation Impact: 4.85

Command Palette

Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia

Authors

Abstract

Topics & Keywords

Publication Details